Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 14:48:44 GMT 2023
by
admin
on
Sat Dec 16 14:48:44 GMT 2023
|
| Protein Sub Type | |
| Sequence Origin | HUMAN |
| Sequence Type | COMPLETE |
| Record UNII |
SV6QS63US6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SV6QS63US6
Created by
admin on Sat Dec 16 14:48:45 GMT 2023 , Edited by admin on Sat Dec 16 14:48:45 GMT 2023
|
PRIMARY | |||
|
P32246
Created by
admin on Sat Dec 16 14:48:45 GMT 2023 , Edited by admin on Sat Dec 16 14:48:45 GMT 2023
|
PRIMARY |
| From | To |
|---|---|
| 1_106 | 1_183 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| N | 1_5 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR -> TARGET |
Efficacious in multiple myeloma in preclinical but ineffective in phase II clinical trials for multiple sclerosis.
Ki
|
||
|
INHIBITOR -> TARGET |
Compound
Inhibited recruitment of immune cells induced by CCL3, but a phase II trial investigating rheumatoid arthritis was terminated due to no discernible activity in patients with rheumatoid arthritis at a concentration of 10 mg once daily.
|
||
|
INHIBITOR -> TARGET |
Binding Assay
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Binding assay
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|